Mario Gimona,
Head of Manufacturing, GMP Unit,
Paracelsus Medical University Salzburg
Mario Gimona received his PhD in Genetics and Cell Biology in 1990 and spent his postdoctoral period at the Cold Spring Harbor Laboratory in New York. He has led research labs in Austria and Italy and was awarded a Marie Curie Excellent Grant by the European Union in 2004. Since 2012 he heads the GMP stem cell and EV production unit at PMU and leads a team of researchers investigating the potential of MSC-derived EVs and CDVs in regenerative medicine for application in acute spinal cord injury and for the reduction of scar formation following implant-induced injury.
EVs and CDVs: Nanovesicle Therapeutics and Drug Delivery Systems
Tuesday, 25 October 2022 at 09:30
Add to Calendar ▼2022-10-25 09:30:002022-10-25 10:30:00Europe/LondonEVs and CDVs: Nanovesicle Therapeutics and Drug Delivery SystemsExtracellular Vesicles and Nanoparticle Therapeutics Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Nanovesicle-based therapy is increasingly being pursued as a safe, cell-free strategy to combat various immunological, musculoskeletal and neurodegenerative diseases. Small secreted extracellular vesicles (sEVs) obtained from multipotent mesenchymal stromal cells (MSCs) are of particular interest for therapeutic use since they convey anti-inflammatory, anti-scarring and neuroprotective activities to the recipient cells. A novel drug delivery platform technology that is based on cell-derived vesicles (CDVs) produced by a proprietary extrusion process generates nanosized vesicles that are surrounded by a lipid bilayer membrane with a correct membrane topology and that display biological activities similar to MSC-derived EVs. Translation of nanovesicle-based therapeutics into clinical application requires quantitative, and reproducible analysis of bioactivity and stability. The GPI-anchored ecto-5’-nucleotidase CD73 is abundantly present on MSC-derived EVs and CDVs and efficiently converts AMP to Adenosine. In an in-vitro assay the enzymatic activity per particle correlated with CD73 abundance and we reproducibly obtained 2 - 8 x 10-8 mM Adenosine production / particle in both sEV and CDV preparations. Nucleotides can work as trophic, differentiating, and immunomodulatory molecules in many physiological and pathological situations through autocrine and paracrine mechanisms, and purinergic ligands are potent candidates to mediate cellular crosstalk and to promote cell growth and survival, regulate inflammation and contribute to local tissue homeostasis and repair. Our data suggest that CD73-mediated Adenosine signaling supports the creation of an anti-inflammatory and pro-regenerative environment that can pave the road to tissue repair and functional regeneration.
Add to Calendar ▼2022-10-24 00:00:002022-10-25 00:00:00Europe/LondonExtracellular Vesicles and Nanoparticle Therapeutics Europe 2022Extracellular Vesicles and Nanoparticle Therapeutics Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2022-10-25 09:30:002022-10-25 10:30:00Europe/LondonEVs and CDVs: Nanovesicle Therapeutics and Drug Delivery SystemsExtracellular Vesicles and Nanoparticle Therapeutics Europe 2022 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
